New Studies Validate Prognostic Value of Agendia’s MammaPrint in Breast Cancer

Researchers from Agendia and MD Anderson presented findings at ASCO’s annual meeting, suggesting that when used in conjunction with other gene-expression assays, Agendia’s MammaPrint, which is indicated to predict metastasis, can help determine which patients’ breast cancer will recur and whether they should be treated with endocrine therapy or chemotherapy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.